Ultragenyx CEO to Discuss Rare Disease Pipeline at Goldman Sachs Conference
Event summary
- Ultragenyx CEO Emil Kakkis to participate in fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 4:00 PM ET.
- Webcast of the event will be available live and archived on Ultragenyx’s investor relations website.
- Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases.
- Company emphasizes time- and cost-efficient drug development for high unmet medical needs.
The big picture
Ultragenyx’s participation in the Goldman Sachs conference underscores its focus on engaging with key investors and analysts to discuss its pipeline and strategic direction. The event comes at a time when the rare disease therapeutics sector is seeing increased competition and regulatory scrutiny, making it critical for Ultragenyx to demonstrate its unique value proposition. The company’s emphasis on efficient drug development reflects broader industry trends toward cost-effective innovation in niche therapeutic areas.
What we're watching
- Pipeline Progress
- How Ultragenyx’s pipeline advancements will be highlighted and whether they align with investor expectations.
- Strategic Shifts
- Whether the company will signal any strategic pivots in its rare disease focus during the conference.
- Market Positioning
- The pace at which Ultragenyx can differentiate itself in the competitive rare disease therapeutics space.